Risperidone vs Paliperidone

How they're similar

The two drugs share more than they differ, which is expected given the metabolite relationship.

• Both are second-generation atypical antipsychotics.
• Both are FDA-approved for schizophrenia. Paliperidone is also approved for schizoaffective disorder, both as monotherapy and as an adjunct to mood stabilizers or antidepressants. Risperidone is approved for bipolar mania, both alone and as an adjunct, and for autism-related irritability in children and adolescents.
• Both block dopamine D2 receptors and serotonin 5HT2A receptors.
• Both raise prolactin, and both are near the top of the class for that effect. Prolactin-related side effects (breast enlargement, galactorrhea, missed periods, lowered sex drive, erectile problems) are common on both.
• Both can cause extrapyramidal symptoms, especially at higher doses. The risk climbs with the dose.
• Both cause moderate weight gain and modest changes in blood sugar and lipids. Metabolic monitoring is standard for both: weight, blood pressure, fasting glucose, and lipids at baseline, at three months, and then at least annually.
• Both can cause orthostatic hypotension during titration, so slow dose increases are the norm.
• Both carry the class boxed warning about increased mortality in elderly patients with dementia-related psychosis.
• Both come in oral forms and both have long-acting injectable versions.
• Both are available as generics, though the newer long-acting formulations of paliperidone are still expensive.

Because the two drugs share receptor activity and side effect profiles so closely, switching between them rarely solves a side effect problem that's driven by receptor activity itself. A patient who develops prolactin symptoms on risperidone will usually have the same problem on paliperidone. A patient who has EPS on one is likely to have it on the other. Switching between them is more often driven by practical issues like drug interactions, kidney function, or the desire for a specific long-acting injectable option.

How they differ

The differences between risperidone and paliperidone come down to pharmacokinetics and formulation. The mechanism is similar. The metabolic route, dosing, and injectable options are not.

The metabolic difference is where the practical implications start. Risperidone is metabolized in the liver, primarily by the CYP2D6 enzyme, into paliperidone (9-hydroxy-risperidone). That means when a person takes risperidone, their CYP2D6 activity determines how much of it gets converted and how quickly. About 7 to 10% of white and Asian populations, and higher percentages in some other groups, are CYP2D6 poor metabolizers, meaning their bodies don't convert risperidone efficiently. That doesn't necessarily prevent risperidone from working, since the parent drug is also active, but it can lead to higher parent drug levels and potentially different side effect patterns.

More importantly, CYP2D6 is inhibited by a number of common medications, including fluoxetine (Prozac), paroxetine (Paxil), and bupropion (Wellbutrin). When a person on risperidone starts one of those drugs, risperidone levels can rise significantly. That can worsen sedation, EPS, and other dose-related side effects. Paliperidone doesn't have this problem. Because it's the metabolite itself, it doesn't need CYP2D6 to become active, and its levels aren't affected much by CYP2D6 inhibitors. For a patient who's on fluoxetine, bupropion, or paroxetine already, paliperidone is often the cleaner choice.

Kidney function goes the other way. Paliperidone is primarily excreted by the kidneys, meaning its clearance depends on renal function. In patients with mild kidney impairment, the dose usually needs to come down. In moderate to severe kidney impairment, significant dose adjustments are required, and in severe impairment paliperidone may not be a good option at all. Risperidone is cleared through both liver and kidneys, so it's more forgiving in that respect. For a patient with kidney disease, risperidone is often preferred.

The long-acting injectable options are where the two drugs diverge most dramatically. This is a practical difference that shapes how each is used in clinical settings where LAIs are considered.

Risperidone has three LAI options. Risperdal Consta is given every two weeks and was the first atypical LAI on the market. It requires an oral overlap of three weeks after the first injection because it takes that long to reach therapeutic drug levels. Perseris is a monthly subcutaneous injection that doesn't require oral overlap. Uzedy is a subcutaneous injection given monthly or every two months depending on the dose.

Paliperidone has four LAI options, and they represent some of the longest dosing intervals available in psychiatry. Invega Sustenna is monthly. Invega Trinza is every three months, but can only be started after at least four months on Sustenna to establish steady-state levels. Invega Hafyera is every six months, and can only be started after at least four months on Sustenna or at least one dose cycle on Trinza. That progression, from monthly to quarterly to twice-yearly, means paliperidone offers the option of very infrequent dosing for patients who prefer that or who benefit from it. Two shots a year, for some patients, is a much more workable long-term plan than daily pills.

The trade-off with the longer intervals is that dose adjustments take longer to have an effect, and if a patient has a serious side effect, it stays in the system for months. That makes patient selection and stabilization on shorter intervals before moving to longer ones important.

Approved indications differ slightly. Risperidone is approved for schizophrenia, bipolar mania, and autism-related irritability in children and adolescents. Paliperidone is approved for schizophrenia and schizoaffective disorder. The schizoaffective disorder approval is specific to paliperidone in this pair, though risperidone is often used off-label for that indication.

Side effect tendencies

The everyday side effects of the two drugs overlap so closely that patients often can't distinguish them by feel. Both can cause sedation, weight gain, movement effects, prolactin symptoms, orthostatic hypotension, and the anticholinergic effects like dry mouth and constipation.

Prolactin elevation is significant on both. Symptoms include breast enlargement in men, milk production not related to pregnancy, missed or irregular periods in women, lowered sex drive, and erectile problems. Long-term prolactin elevation can also affect bone density. These effects are common enough on both drugs that they're part of routine counseling, and if they appear, that's often a reason to consider a dose reduction or a switch to a lower-prolactin drug like aripiprazole.

Movement effects, or EPS, appear on both, and the risk goes up with the dose. On risperidone, above about 4 mg a day is a common threshold. On paliperidone, similar patterns apply at equivalent doses. Both can cause akathisia (inner restlessness), parkinsonism (stiffness and slowed movement), and tardive dyskinesia over years of use.

Metabolic effects are moderate on both. Neither is as bad as olanzapine or clozapine, but both can cause meaningful weight gain and changes in blood sugar and lipids. Monitoring is the same.

Orthostatic hypotension is common enough during titration that slow dose increases are standard for both. Falls are a specific concern in older patients.

There's no reliable difference in the pattern or severity of these side effects between the two drugs. That's expected, given the metabolite relationship.

What tips the choice

Because the drugs are so similar in effect, the choice usually turns on practical questions.

A clinician might choose paliperidone when a patient is taking a strong CYP2D6 inhibitor like fluoxetine, paroxetine, or bupropion, and the interaction with risperidone would be a problem. Paliperidone sidesteps that interaction entirely.

A clinician might choose paliperidone when a long-acting injectable is being considered and a very infrequent dosing schedule is desirable. The progression from Sustenna to Trinza to Hafyera offers monthly, quarterly, and twice-yearly options that no other antipsychotic matches. For patients whose life would be easier with two shots a year instead of daily pills, that's a real advantage.

A clinician might choose paliperidone when the target diagnosis is schizoaffective disorder specifically, given its FDA approval for that condition.

A clinician might choose risperidone when kidney function is impaired, since paliperidone requires more dose adjustment in that setting. Risperidone is more forgiving in patients with chronic kidney disease.

A clinician might choose risperidone when cost is a concern. Oral risperidone is inexpensive as a generic. Oral paliperidone is more expensive, and the long-acting injectable forms of paliperidone remain expensive even where generic versions are available. Insurance coverage often plays a role in the decision.

A clinician might choose risperidone when treating autism-related irritability in a child, since risperidone is specifically approved for that indication and has more pediatric data to support it.

Prior response weighs in as always. A patient who's done well on one usually stays with that one. A patient who had a specific problem on one is likely to have the same problem on the other, so switching between them to solve a receptor-driven side effect (like prolactin symptoms or EPS) usually isn't the answer. That kind of problem is better addressed with a dose reduction or a switch to a drug with a different mechanism.

Common questions

If paliperidone is the active metabolite of risperidone, are they really different? Pharmacologically they're very similar. The differences aren't at the receptor. They're in how the body handles each drug: which enzymes are involved, how they're cleared, and what dosing forms are available. So while the receptor activity and side effects overlap heavily, the practical differences (drug interactions, kidney effects, injection intervals) can be decisive in a specific patient.

Why would someone on fluoxetine be better off on paliperidone? Fluoxetine is a strong inhibitor of CYP2D6, which is the main enzyme that metabolizes risperidone into paliperidone. When fluoxetine is added to risperidone, risperidone levels can go up significantly, which can worsen sedation, movement effects, and other dose-related side effects. Paliperidone doesn't need CYP2D6 to work, so the interaction with fluoxetine is much smaller. For a patient already on fluoxetine, or on bupropion or paroxetine, paliperidone is often the cleaner choice.

What's special about the paliperidone six-month shot? Invega Hafyera is given every six months, meaning two shots a year. That's the longest dosing interval available for any antipsychotic. It can only be started after a patient has been stable on Invega Sustenna (monthly) for at least four months, or on Invega Trinza (every three months) for at least one dose cycle. The idea is to establish stable drug levels first, then move to less frequent dosing. For patients whose life is easier with fewer clinic visits or who prefer not to think about medication daily, it can be transformative. The trade-off is that dose changes and side effect problems take longer to resolve.

Do these drugs cause the same weight gain? Yes, roughly. Both cause moderate weight gain, less than olanzapine or clozapine but more than aripiprazole or lurasidone. If weight is a major concern, switching between risperidone and paliperidone won't solve it. Moving to a metabolically friendlier drug, or adding metformin, exercise, and diet support, are more likely to help.

Can I switch between them? Yes, and it's straightforward. Because they're so similar, switching is usually done for practical reasons rather than because one isn't working. The dose equivalence is roughly 6 mg of paliperidone to 3 mg of risperidone, though prescribers usually adjust based on how the patient responds. Any switch should be planned with a prescriber.

Sources

This guide draws on current prescribing information and public health references. It is reviewed for clinical accuracy and updated as guidance changes.

1. U.S. Food and Drug Administration. Risperidone (Risperdal) prescribing information.
2. U.S. Food and Drug Administration. Paliperidone (Invega) prescribing information.
3. MedlinePlus, U.S. National Library of Medicine.
4. National Institute of Mental Health. Mental health medications.